Japanese Transgenic Obtains Patent For Pancreatic Cancer Antibody Diagnostic Technology
This article was originally published in PharmAsia News
Japanese biotech venture company Transgenic obtained a patent for pancreatic cancer antibody diagnostic technology. The technology uses antibodies to detect a protein unique to pancreatic cancer patients. Transgenic developed the technology through a joint research project with Japan's National Cancer Center in 2007. Using genetically engineered mice, Transgenic developed the antibody that can be easily combined with the protein. Currently there are few cancer makers for pancreatic cancer diagnose. (Click here for more - Japanese language
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.